Phase II evaluation of dibromodulcitol and actinomycin D,hydroxyurea, and cyclophosphamide in previously untreated patients with malignant melanoma |
| |
| Authors: | David A. Amato Howard Bruckner DuPont Guerry IV Arlene Ash Geoffrey Falkson Ernest C. Borden Richard H. Creech Edwin D. Savlov Thomas J. Cunningham |
| |
| Affiliation: | (1) Dana-Farber Cancer Institute and Harvard School of Public Health, (CA 23318) Boston, MA;(2) University of Rochester Cancer Center, (CA 11083) Rochester, NY;(3) Cancer Center, Hospital of the University of Pennsylvania, (CA 15488) Philadelphia, PA;(4) University of Pretoria, (CA 21692) Pretoria, South Africa;(5) University of Wisconsin Clinical Cancer Center, (CA 21076) Madison, WI;(6) Fox Chase Cancer Center, (CA 18281) Philadelphia, PA;(7) Albany Medical College, (CA 06594) Albany, NY, USA;(8) Division of Biostatistics and Epidemiology, Dana-Farber Cancer Institute, 44 Binney Street, 02115 Boston, MA, USA |
| |
| Abstract: | In this Eastern Cooperative Oncology Group (ECOG) phase II study, dibromodulcitol (DBD) and a combination of actinomycin D, hydroxyurea, and cyclophosphamide (AHC) were compared with methyl-CCNU, the current ECOG standard, in patients who had received no prior chemotherapy for disseminated malignant melanoma. The response rates were 6% (3/50) for AHC, 9% (3/34) for DBD, and 14% (7/49) for methyl-CCNU. Median survival times were 4, 5, and 6 months, respectively. Neither regimen appears to offer any advantage over methyl-CCNU as front-line therapy for patients with disseminated melanoma. |
| |
| Keywords: | melanoma dibromodulcitol actinomycin D hydroxyurea cyclophosphamide methyl-CCNU |
| 本文献已被 SpringerLink 等数据库收录！ |
|
